新型DIO1基因突变作为表型修饰因子影响TPO基因复合杂合突变所致先天性甲状腺功能减退症
在一个先天性甲状腺功能减退症家系中发现两个新型TPO基因复合杂合致病突变(c.962C>A和c.1577C>T),血清甲状腺功能检查显示游离T4相对TT3高于预期,且反T3(rT3)也升高。两名同胞相较另一名同胞表现出更严重的发育迟缓表型,并发现额外携带一个新型DIO1基因杂合致病突变(c.395G>A)。在L-T4替代治疗背景下,D1活性降低导致甲状腺激素代谢异常,使L-T4生成T3减少,可能在发育关键阶段降低T3生物利用度。
要点
- TPO复合杂合突变(c.962C>A、c.1577C>T)可致先天性甲减,血清游离T4相对TT3偏高且rT3升高。
- DIO1杂合突变(c.395G>A)可能作为表型修饰因子加重发育迟缓。
- L-T4治疗时D1活性降低可减少T3生成,需关注发育关键期T3生物利用度。
核心结论
- 新型DIO1基因突变(c.395G>A)可能作为表型修饰因子,加重TPO复合杂合突变所致先天性甲减的发育迟缓表型。
研究设计与样本
- 研究对一个先天性甲状腺功能减退症家系进行了基因检测和临床表型分析。
主要发现
- 家系中鉴定出两个新型TPO复合杂合致病突变(c.962C>A和c.1577C>T)。
- 血清甲状腺功能检查显示游离T4相对TT3高于预期,且rT3升高。
- 两名携带额外DIO1杂合突变(c.395G>A)的同胞较另一名同胞表现出更严重的发育迟缓表型。
关键数值与推荐
- TPO突变:c.962C>A和c.1577C>T复合杂合。
- DIO1突变:c.395G>A杂合。
- 血清学:游离T4相对TT3高于预期,rT3升高。
临床怎么用
- 对先天性甲减患者应关注TPO之外的其他基因变异(如DIO1)对表型的修饰作用。
- L-T4替代治疗时需考虑D1活性降低可能影响T3生成,关注发育关键期T3生物利用度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A family with congenital hypothyroidism was identified with two novel deleterious compound heterozygous thyroid peroxidase (TPO) mutations (c.962C>A, and c.1577C>T). Serum thyroid tests showed higher-than-expected serum-free thyroxine (T4) relative to TT3, while reverse triiodothyronine (rT3) was also elevated. Two siblings manifested a more severe phenotype of developmental delay compared with another sibling and were found to harbor an additional novel heterozygous deleterious iodothyronine deiodinase 1 (DIO1) mutation (c.395G>A). In the context of L-T4 replacement, the decreased D1 activity results in abnormal thyroid hormone metabolism with decreased triiodothyronine (T3) generation from L-T4 and may result in decreased T3 bioavailability during critical stages of development.
引用
- Furman A, Hannoush Z, Echegoyen FB, et al. Novel DIO1 Gene Mutation Acting as Phenotype Modifier for Novel Compound Heterozygous TPO Gene Mutations Causing Congenital Hypothyroidism. Thyroid. 2021. PMID: 34128397. doi:10.1089/thy.2021.0210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。